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Growing teratoma syndrome is a rare condition among patients with nonseminomatous germ cell
tumors who present with enlarging metastatic masses during appropriate systemic chemotherapy and
normalized serum markers. Retroperitoneal residual masses are a common ﬁnding after chemotherapy
for the nonseminomatous tumors of the testis. These might contain mature teratoma, ﬁbrotic tissue, or
tumor. Mature teratoma, which is unresponsive to chemotherapy, might result from evolution of a
malignant lesion during treatment or it might represent a metastasis from a focus of mature teratoma in
the primary testicular tumor. This article reviews a case of a growing teratoma syndrome.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.Introduction
The efﬁciency of chemotherapy on nonseminomatous germ cell
tumors (NSGCTs) is no longer to be demonstrated. The existence of
a residual mass at the end of the treatment requires the excision of
the former. That is, in fact, the only way to afﬁrm the histologic
nature conditioning the subsequent conduct of the treatment.1 The
pathologic analysis of these residual masses might reveal either
the persistence of malignant cells or the presence of a ﬁbrosis, a
necrosis, or ﬁnally, the existence of a mature teratoma.2 The latter
situation has been encountered in our patient.Case presentation
A 19-year-old patient consulted for a swelling of the left
testicular. The clinical examination found a large, ﬁrm abdominal
mass, attached to the deep plane, localized at the left ﬂank. The
examination of the external genital organs found an enormousthe terms of the Creative
Works License, which per-
on in any medium, provided
21 373200669.
a).
Published by Elsevier Inc. All righmass at the left testicular of 15-cm long axis without associated
inﬂammatory signs. An abdominal and pelvic computed tomog-
raphy (CT) revealed a left retroperitoneal mass measuring 8  6
cm displacing the aorta to the right and compressing the left
ureter (Fig. 1A) with bilateral hilar lymph nodes (maximum
diameter 28 mm). It also showed a left testicular mass measuring
10  10 cm.
Serum tumor markers were twice as high as the normal. Our
patient had an orchiectomy followed by 3 cycles of chemotherapy
(bleomycin, cisplatin, and etoposide) for a stage IIC mixed NSGCT
containing a teratomatous component and an embryonal carci-
noma. Serum tumor markers were normalized after the ﬁrst cycle
of chemotherapy.
At initial staging, hilar lymph nodes have regressed on CT data,
instead the retroperitoneal mass has increased (maximum diam-
eter 12  12 cm; Fig. 1B).
Our patient had a second e line chemotherapy (ifosfamide plus
etoposide and cisplatin). Two months later, a comparative
abdominal scanner has shown that the retroperitoneal mass
continued to increase (maximum diameter was 12  15 cm) and
was responsible of a hydronephrosis. Clinically, the patient com-
plained of an abdominal discomfort.
Given the negative tumor marker and the imaging features,
growing teratoma syndrome (GTS) was hypothesized. The patient
underwent surgery that consisted of a complete resection of the
mass.ts reserved.
Figure 1. (A) Retroperitoneal mass measuring 8  6 cm displacing the aorta to the right and compressing the left ureter. (B) Growing retroperitoneal mass measuring 12  12 cm.
W. Boukettaya et al. / Urology Case Reports 2 (2014) 1e32Pathologic examination of the resected lesion conﬁrmed the
diagnosis of mature teratoma in his multicystic form (Fig. 2)
without viable tumor.
Eighteen months later, our patient is in good health without any
local or distant recurrence.
Discussion
The term GTS was coined by Logothetis et al, in 1982, to describe
a rare entity among patients with NSGCTs, characterized by
enlarging metastatic masses despite appropriate systemic chemo-
therapy and normalized serummarkers. The diagnosis is conﬁrmed
by the presence of mature teratoma and the absence of any ma-
lignant germ cells on ﬁnal surgical pathology.
The prevalence of GTS in metastatic NSGCT is between 1.9% and
7.6%.3 GTS is most commonly observed in the retroperitoneum but
has also been described in the lung, mediastinum, supra clavicular
lymph nodes, inguinal lymph nodes, forearm, mesentery, and liver.
Our patient presented a retroperitoneal localization.
The etiology of GTS is unclear. The 2 most-quoted theories are
that chemotherapy destroys only the immature malignant
cells, leaving the mature benign teratomatous elements, and4
chemotherapy alters the cell kinetics toward transformationFigure 2. Teratoma in his multicystic form.from a totipotent malignant germ cell toward a benign mature
teratoma.
A third hypothesis offered by Hong et al5 proposes an inherent
and spontaneous differentiation of malignant cells into benign
tissues, as suggested by the experimental murine teratocarcinoma
mouse model. In our case, the probable assumption is the trans-
formation of the nonseminomatous tumors into a mature teratoma
because the mass existed at the beginning of treatment.
GTS poses a diagnostic challenge for both medical oncologists
and urologists because of its rarity and unusual presentation.
A growing mature teratoma is characterized by enlarging met-
astatic masses, despite appropriate systemic chemotherapy and
normalized serum markers. The preferred treatment is complete
surgical resection because teratoma was resistant to chemotherapy
and radiation therapy.6 The chemotherapy used before establishing
a diagnosis of GTS includes a variety of single agents, such as acti-
nomycin D or cyclophosphamide, or various combinations of
adriamycin, bleomycin, etoposide, vinblastine, cyclophosphamide,
chlorambucil, methotrexate, nitrogen mustard, and cisplatin.6
In our case, we have administrated a second line of chemo-
therapy (ifosfamide plus etoposide and cisplatin), but the retro-
peritoneal mass continues to increase, and the surgical treatment
was indicated only when patient presented an uretero-pyelocalicial
expansion.
Finally, growing mature teratoma is unresponsive to systemic
chemotherapy and requires surgical excision to avoid malignant
transformation or complications such as compression of adjacent
structures such as an ureterohydronephrosis, subocclusive syn-
dromes, venous, and lymphatic stasis.7
Although GTS has an excellent prognosis, regular follow-up is
critical, as very late malignant masses do occur in some patients. In
fact, in an effort to avoid late diagnosis of GTS, Spiess et al8
recommend regular imaging in patients undergoing chemo-
therapy, possibly after 2 cycles of chemotherapy, to ensure careful
monitoring of subtle changes in tumor size and appearance. Im-
aging ﬁndings and tumor markers can suggest the presence of
mature lesions, but surgical excision or sampling of the lesions is
mandatory to exclude recurrent malignancy.4Conclusion
A growing mature teratoma is a progressive form of NSGCT
characterized by a negative tumor marker and a speciﬁc CT scan
features. It is unresponsive to chemotherapy testicular tumors. The
only treatment is surgical excision to avoid its complications.
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